Pemigatinib plus afatinib for advanced solid tumors with FGFR changes
Treatments studied
Part of Cancer clinical trials.
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor (like cancer in the bile ducts or another organ) that has not responded to standard treatments or for which there is no standard treatment.
- Your tumor has a specific genetic change called an FGFR1-3 fusion, rearrangement, or activating mutation, found through a special lab test.
- You are at least 18 years old, able to swallow pills, and have a life expectancy of at least 3 months.
- You are in good enough physical health to do daily activities (like walking and light work) without needing help.
- Your liver, kidney, and blood test results are within acceptable ranges, and you do not have serious heart or lung problems, active brain tumors, or uncontrolled infections.
- If you have bile duct cancer (cholangiocarcinoma), you may need to be in a specific group depending on whether you have had a prior FGFR inhibitor treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two medications—pemigatinib and durvalumab—for people with advanced bile duct or gallbladder cancer that has stopped responding to prior treatment and has a specific genetic change (FGFR2 fusion). The goal is to see if this combination can shrink or control the cancer better.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
This trial tests a targeted drug called pemigatinib for advanced solid tumors that have a specific change in the FGFR gene. The goal is to see if the drug can slow tumor growth for people who have few other treatment options.
This trial tests a combination of two drugs—pemigatinib, which targets tumors with certain FGFR gene changes, and an immunotherapy drug that helps the immune system fight cancer—for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
This Phase 2 trial tests pemigatinib, a targeted medicine, for advanced or metastatic gastrointestinal (GI) cancers that have specific FGFR1–3 gene changes. It’s for people whose cancer has grown despite prior standard treatment, and who may benefit if their tumor has the right genetic change.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.